Nutrisystem (NTRI) Tops Q1 EPS by 8c; Guides Higher

Nutrisystem (NASDAQ: NTRI) reported Q1 EPS of $0.13, $0.08 better than the analyst estimate of $0.05. Revenue for the quarter came in at $162.1 million versus the consensus estimate of $152.13 million.

awn Zier, President and Chief Executive Officer, stated, “The Nutrisystem brand continues to resonate well with customers. Turbo10, Turbo shakes, and new flexible options drove better-than-expected first quarter results. Our unique combination of easy-to-use, highly effective weight-loss products provides a strong value proposition that has made Nutrisystem a leading name in weight-loss. We continue to execute on our strategic initiatives and believe our investments in new products and further enhancements to the customer experience have us well positioned to achieve our third consecutive year of double-digit revenue growth.”

Ms. Zier added, “Looking ahead, we are focused on unlocking additional value to propel our future growth. We are on track to launch the South Beach Diet for the 2017 diet season and continue to test Shake360, which is being targeted to a new demographic of customers. We believe these initiatives, coupled with the continued development and growth of our core brand, will position Nutrisystem to capture a greater share of the expanding weight-loss market and further penetrate the broader health and wellness space.”

GUIDANCE:

Nutrisystem sees Q2 2016 EPS of $0.48-$0.53, versus the consensus of $0.46. Nutrisystem sees Q2 2016 revenue of $145-150 million, versus the consensus of $145.1 million.

Nutrisystem sees FY2016 EPS of $1.03-$1.13, versus prior guidance of $0.95-$1.02 and the consensus of $0.99. Nutrisystem sees FY2016 revenue of $517-532 million, versus the consensus of $514.04 million.

For earnings history and earnings-related data on Nutrisystem (NTRI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Applied Materials (AMAT) Tops Q3 EPS by 10c, Offers Guidance
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery